SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following its CEO's significant presentation at a major cancer summit outlining breakthroughs in 'chemo-free' treatments and recent international regulatory approvals for its ANKTIVA therapy. The community is actively discussing the stock's "unstoppable" scientific progress and the potential for a substantial short squeeze fueled by high short interest.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical ($DRTS) is trending as the community anticipates imminent Japanese marketing approval for its Alpha DaRT cancer treatment, further validated by successful glioblastoma patient outcomes and growing institutional interest, positioning the company for significant global commercial expansion.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Donald Trump's State of the Union address is driving immediate conversation around DJT, generating intensely polarized reactions with supporters praising his "epic" speech while detractors label it a "clown show" "full of lies." Community discussions actively center on his policy claims regarding tariffs, immigration, and the economy, alongside renewed chatter on Epstein-related allegations.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending as Paramount Skydance's significantly revised all-cash offer, now at $31 per share plus a ticking fee and commitment to cover Netflix's breakup cost, has prompted WBD's board to consider it a potentially superior proposal. The community is sharply divided on whether Netflix will increase its own complex bid or opt to accept the breakup fee amidst mounting regulatory concerns and debt implications.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the bidding war for Warner Bros. Discovery intensifies with Paramount's revised offer, igniting strong community discussion on whether Netflix should raise its bid or walk away to collect a substantial breakup fee, all while facing heightened regulatory and political pressure.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending due to upcoming earnings and intense debate surrounding the CLARITY Act's impact on stablecoin yields, with bulls highlighting growing institutional adoption and USDC's foundational role while bears cite regulatory uncertainty, past insider selling, and its price correlation to broader crypto market volatility.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as Warner Bros. Discovery re-evaluates its acquisition offers, granting a limited waiver to re-engage with PSKY following its revised, all-cash bid including substantial regulatory breakup and ticking fees. The community is actively discussing PSKY's offer as potentially superior against Netflix's, while also weighing concerns about the massive debt PSKY would incur if successful.

HP Inc. is an information technology company, which engages in the provision of personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services. It operates through the following segments: Personal Systems, Printing, and Corporate Investments. The Personal Systems segment offers commercial and consumer desktop and notebook personal computers, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, solutions and services, and scanning devices. The Corporate Investments segment includes HP Labs and certain business incubation projects. The company was founded by William R. Hewlett and David Packard in 1939 and is headquartered in Palo Alto, CA.

HP Inc

HP Inc. is trending as its latest earnings report paints a divided picture for investors, with weak near-term profit guidance, impacted by U.S. tariffs and supply chain shifts, sparking bearish concerns. Conversely, many in the community are emphasizing the company's compelling value, robust free cash flow, and recently increased dividend, alongside the long-term growth prospects from AI-powered PCs.

Fortuna Mining Corp. engages in the exploration, extraction and processing of precious and base metal in Latin America. It operates through the following segments: Minera Bateas S.A.C (Bateas), Compania Minera Cuzcatlan S.A. de C.V. (Cuzcatian), Mansfield Minera S.A. (Mansfield), and Corporate. The Beates segment operates the Caylloma silver, lead, and zinc mine. The Cuzcatlan segment handles the San Jose silver-gold mine. The Mansfield segment constructs the Lindero mine. The Corporate segment represents the corporate stewardship. The company was founded by Jorge Alberto Ganoza Durant, Simon T. P. Ridgway, and Mario David Szotlender on September 4, 1990 and is headquartered in Vancouver, Canada.

Fortuna Mining Corp.

Fortuna Silver Mines Inc.

Fortuna Silver Mines (FSM) is a trending topic following recent positive exploration results at its Diamba Sud Gold Project and strong cash flow from its latest earnings, alongside strategic asset sales. Despite the backdrop of 'flying' gold and silver prices, community sentiment is mixed, with many highlighting the stock's perceived undervaluation while others voice frustration over its lagging market performance.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

Cava Group is trending following its earnings report, which showcased robust revenue growth and restaurant expansion, pushing its annual revenue past $1 billion. The community is actively debating the company's valuation and decelerating same-store sales against its ambitious growth plans and strong digital performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday...

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the Health and Human Services Department, led by Robert F. Kennedy Jr., plans to "drastically" cut federal funding for domestic HIV prevention.While cuts have not been finalized, the Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-administration-weighing-major-cuts-to-funding-for-domestic-hiv-prevention-8dcad39b?mod=Searchresults_pos1&amp;page=1&amp;mod=article_inline&amp;adobe_mc=MCMID%3D74537243080012175182679892959762943330%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1742440495&amp;_gl=1*1myqz7*_gcl_au*NTUzNDY5MDY4LjE3MzUyMTA0MzI.*_ga*MTg1Mzg3MjI1NS4xNzE4OTcyNDYz*_ga_K2H7B9JRSS*MTc0MjQ0MDIzNy4yNi4xLjE3NDI0NDA0OTMuNjAuMC4w">reported</a>, citing people familiar with the matter, that they could be announced soon as part of the Trump administration's broader budget reductions at the Centers for Disease Control and Prevention.Gilead, which has a portfolio of HIV prevention treatments such as Biktarvy and Descovy, risks a hit to revenues if the report turns out to be true.However, retail investors and Wall Street analysts remain largely unfazed for now.Retail sentiment for Gilead on Stocktwits climbed further into the 'extremely bullish' zone on Wednesday, with message volume up 57% following the news.&nbsp;<figure class="image"><img style="aspect-ratio:1318/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/GILD_sentiment_and_message_volume_as_of_March_19_png_baa27803b8.webp" alt="GILD sentiment and message volume as of March 19.png" width="1318" height="302"><figcaption>GILD sentiment and message volume as of March 19. | source: Stocktwits</figcaption></figure>Observers on the platform cited Gilead's dominance in HIV treatments, growing oncology presence, and strong free cash flow as reasons to hold on to the stock.<stembedurl>https://stocktwits.com/Bitcoin333/message/608542775</stembedurl><stembedurl>https://stocktwits.com/skcots131313/message/608543583</stembedurl>According to The Fly, JPMorgan acknowledged that the WSJ report is "clearly not a positive" but says the potential cuts wouldn't impact access to PrEP (pre-exposure prophylaxis). The firm noted that the CDC doesn't reimburse PrEP drugs but funds research and education.&nbsp;The research firm remains bullish on Gilead's lenacapavir — a twice-yearly injectable HIV-1 capsid inhibitor — as a key growth driver and maintains an 'Overweight' rating on the stock.Oppenheimer sees Gilead's pullback as a reaction to uncertainty but doesn't view the funding concerns as a material risk. The firm estimates PrEP revenues account for just 8% of Gilead's total sales, with Medicaid representing an even smaller fraction.&nbsp;It expects early lenacapavir adoption mostly from private insurers and reiterated an 'Outperform' rating with a $132 price target.If approved by the Food and Drug Administration, Morgan Stanley reportedly estimates that lenacapavir could generate annual sales of over $6 billion by 2030.According to Koyfin data, Gilead stock currently trades at a 13.5x forward earnings multiple, compared to Eli Lilly's 36.1x and Amgen's 15.3x.Shares of Gilead are up 16% this year, outperforming the NASDAQ Biotechnology Index's 3% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

Equity

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.


Shares of Altimmune Inc. are down more than 23% this year, but that has not deterred retail investors from losing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-q4-2024-earnings/chdgfF2RyA">hope</a> in the clinical-stage biotech company.The company has gained traction for its lead candidate,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-on-phase-2-obesity-drug-trial-data/c7zs1ZqRP8">pemvidutide</a>, a GLP-1/glucagon dual receptor agonist being developed for obesity and MASH. In a mid-stage trial, the drug showed that it helped patients reduce their weight by more than 15%.&nbsp;At its R&amp;D Day last week, Altimmune provided more cheer as it unveiled plans to test pemvidutide for treating alcohol use disorder and alcohol-associated liver disease in the second and third quarters of this year.According to The Fly, Evercore ISI said it likes Altimmune's latest expansion and suggested that pemvidutide could rake in more revenue for the new goals than MASH, as 35 million people in the U.S. alone suffer from alcohol use disorder and alcohol-associated liver disease.The research firm added that there is some preclinical and anecdotal evidence to support its thesis.Assuming all goes well, Altimmune will need to fund a Phase 3 program later this year in addition to the AUD/ALD studies, said Evercore, which has an Outperform rating on the shares and a price target of $25.Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. Last year's key&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/alt-stock-slides-after-new-cfo-retail-raises-speculation/cJ4g6IuRO9">C-suite hire</a> at a "pivotal time" for Altimmune bolstered their belief.A Betaville&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.msn.com/en-us/money/companies/altimmune-soars-amid-takeover-speculation/ar-AA1AWioc">report</a> suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms — one FTSE-100 listed, one German, and one U.S.-based — may be involved.<figure class="image"><img style="aspect-ratio:1320/710;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ALT_Stocktwits_poll_on_March_18_png_3a31e58347.webp" alt="ALT Stocktwits poll on March 18.png" width="1320" height="710"><figcaption>ALT Stocktwits poll on March 18. | source: Stocktwits</figcaption></figure>One bullish user said it's "not if, but when [a deal happens]. Too much TAM [total addressable market] for this pipeline of a molecule."<stembedurl>https://stocktwits.com/artiebet/message/608157454</stembedurl>Another user speculated a buyout could happen "within three months," noting the stock is "heading north each week" with "higher lows, higher highs."<stembedurl>https://stocktwits.com/LiveNow1225/message/608159514</stembedurl>Altimmune's stock, which was&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-addition-to-nasdaq-biotech-index/cJaozG7RSI">added</a> to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. | Image source: Getty Images

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

Altimmune Shares Sink In 2025, But Retail Traders Are Optimistic About A Buyout

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.


Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended gains in after-hours trading. Retail buzz on Stocktwits surged, hitting a three-month high.The clinical-stage biopharma company reported a net loss of $23.2 million, or $0.33 per share, for Q4 2024 — an improvement from a $31.6 million loss ($0.54 per share) a year ago.&nbsp;Altimmune ended the year with $132 million in cash and investments, which it expects to fund operations well into the second half of 2026, covering key milestones, including the Phase 2b readout for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) next quarter.CEO Vipin K. Garg said the IMPACT trial was one of "the fastest enrolling biopsy-driven Phase 2b MASH trials, reflecting pemvidutide's appeal due to its potent reduction of liver fat and body weight.""We are confident it will achieve statistically significant improvements in both MASH resolution and fibrosis at trial readout."Altimmune also said it had secured FDA clearance for two additional indications submitted under Investigational New Drug (IND) applications in Q4, with Phase 2 efficacy studies set to begin mid-2025. The company plans to unveil details at its virtual R&amp;D Day on March 13.Retail sentiment on Stocktwits turned 'extremely bullish,' with message volume soaring 273% in the 24 hours leading to Thursday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ALT_sentiment_and_message_volume_Feb_27_1ee28571fe.png" alt="ALT sentiment and message volume Feb 27.png" width="1316" height="316"><figcaption>ALT sentiment and message volume Feb 27 | source: Stocktwits</figcaption></figure>One user predicted a sharp rally to $50, interpreting comments from Altimmune's chief scientific officer that pemvidutide "is the best drug for many indications."<stembedurl>https://stocktwits.com/romanaround/message/606129604</stembedurl>Another speculated on the new INDs, saying they could be for dyslipidemia (or hypertriglyceridemia) and Cirrhosis.<stembedurl>https://stocktwits.com/Cryptobearcat/message/606145193</stembedurl>Altimmune's lead candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist being developed for obesity and MASH.&nbsp;The stock drew attention in December after being <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-addition-to-nasdaq-biotech-index/cJaozG7RSI">added</a> to the Nasdaq Biotechnology Index (NBI).Shares of Altimmune are down over 12% year-to-date.&nbsp;According to Koyfin data, eight of the nine analysts covering the stock rate it a 'Buy' or 'Strong Buy,' while one has a 'Hold' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print

The company plans to unveil details at its virtual R&D Day on March 13.

Shares of Altimmune, Inc. climbed early on Thursday, recovering from a nearly 6% drop in the previous session, drawing significant retail attention.&nbsp;The stock became one of the top three trending symbols on Stocktwits during early trading after the company announced its inclusion in the Nasdaq Biotechnology Index ($NBI) starting Dec. 23.<a href="https://stocktwits.com/news-articles/markets/5/alt-stock-slides-after-new-cfo-retail-raises-speculation/cJ4g6IuRO9">Altimmune</a>, a clinical-stage biotech firm, is currently developing pemvidutide for obesity and metabolic dysfunction-associated steatohepatitis (MASH).&nbsp;CEO Vipin Garg said, “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company.”“With a number of significant inflection points coming in 2025, including the topline data from the Phase 2b IMPACT trial of pemvidutide in MASH in the second quarter, we believe that we are well positioned heading into the new year,” he added.The Nasdaq Biotechnology Index, established in 1993, tracks the performance of Nasdaq-listed biotech and pharmaceutical companies that meet strict criteria such as market capitalization, trading volume, and seasoning requirements.&nbsp;The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.On Stocktwits, retail sentiment for Altimmune shifted from ‘neutral’ to ‘extremely bullish,’ accompanied by a sharp rise in message volume.&nbsp;<stembedurl>https://stocktwits.com/romanaround/message/597152901</stembedurl><stembedurl>https://stocktwits.com/Designed2Gain/message/597160936</stembedurl>A poll on the platform revealed that 52% of retail investors believe the NBI addition will provide a significant long-term boost to the stock, while 22% expect minimal impact.<a href="https://stocktwits.com/symbol/ALT">Altimmune’s shares</a> got a boost last month following better-than-expected quarterly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/altimmune-q3-loss-narrows/cJ40TqmROm">earnings</a> and positive updates on pemvidutide.&nbsp;The company reported a successful FDA meeting that finalized its Phase 3 obesity program design, with no major safety concerns raised.&nbsp;Analysts like H.C. Wainwright’s Patrick Trucchio have expressed confidence in the drug’s differentiation within the GLP-1 agonist space, citing robust efficacy attributes and a well-defined clinical program.Still, Altimmune’s stock remains down nearly 30% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Nasdaq company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds

The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

NBI
NASDAQ Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Latest NBI News

NBINASDAQ Biotechnology